Bruce A Luxon
Bruce A Luxon
Hepatology has matured significantly over the past two decades, and most gastroenterologists now believe that it is a distinct subspecialty. An unmet public health need exists for professional expertise in the care of patients with liver di...
Mitchell L Shiffman
Mitchell L Shiffman
Treatment for chronic hepatitis C virus (HCV) infection is the combination of a peginterferon and ribavirin. Although a fixed duration of treatment (24 weeks for patients with genotypes 2 and 3 and 48 weeks for patients with all other genot...
Fred Poordad,Grace M Chee
Fred Poordad
Hepatitis B is a DNA virus affecting hundreds of millions of individuals worldwide. As the clinical sequelae of cirrhosis and hepatocellular cancer are increasingly recognized to be related to viral levels, the impetus increases to offer tr...
Michael L Schilsky,Aftab Ala
Michael L Schilsky
Wilson disease, a genetic disorder of copper metabolism, presents typically in the second and third decades of life with hepatic or neuropsychiatric disease. Clinical presentations often vary depending on age and degree of onset; although c...
Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH [0.03%]
非甘油三酯类肝毒性：NASH发病机制的新范式
Brent A Neuschwander-Tetri
Brent A Neuschwander-Tetri
Lipid droplet accumulation and oxidant stress, once thought to play essential roles in the pathogenesis of nonalcoholic steatohepatitis (NASH), may actually represent parallel epiphenomena. Emerging data now point to nontriglyceride lipotox...
Stephen Caldwell
Stephen Caldwell
Cryptogenic cirrhosis remains a common clinical condition although recent advances have allowed for a better understanding of underlying conditions and associations. The evolving terminology applied to this condition has resulted in some co...
Jorge L Santos,Monique Choquette,Jorge A Bezerra
Jorge L Santos
Inherited syndromes of intrahepatic cholestasis and biliary atresia are the most common causes of chronic liver disease and the prime indication for liver transplantation in children. Our understanding of the pathogenesis of these diseases ...
Alexander James Thompson,Keyur Patel
Alexander James Thompson
Progressive hepatic fibrosis is the final common pathway for most chronic liver injuries, leading to cirrhosis with risk of liver failure and hepatocellular carcinoma. It is now recognized that fibrosis is a dynamic process, and may be reve...
Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis [0.03%]
原发性胆汁性肝硬化和原发性硬化性胆管炎的最新及新兴疗法
Claudia O Zein,Keith D Lindor
Claudia O Zein
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two most common causes of chronic cholestatic liver disease in adults. In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with ta...
Phenotypic expression of hereditary hemochromatosis: what have we learned from the population studies? [0.03%]
遗传性血色素沉着症的表型表达：人群研究已经告诉了我们什么？
Eng K Gan,Oyekoya T Ayonrinde,Debbie Trinder et al.
Eng K Gan et al.
Profound advances in our knowledge of hereditary hemochromatosis (HH) during the past 150 years have resulted in two distinct "iron ages": the pre-HFE gene era and the post-HFE gene era. During these periods, family studies, HLA association...